- Home
- KC vs CRNX Comparison
KC vs CRNX Comparison
Compare KC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KC
- CRNX
- Stock Information
- Founded
- KC 2012
- CRNX 2008
- Country
- KC China
- CRNX United States
- Employees
- KC N/A
- CRNX N/A
- Industry
- KC Computer Software: Prepackaged Software
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- KC Technology
- CRNX Health Care
- Exchange
- KC Nasdaq
- CRNX Nasdaq
- Market Cap
- KC 3.2B
- CRNX 2.8B
- IPO Year
- KC 2020
- CRNX 2018
- Fundamental
- Price
- KC $11.59
- CRNX $30.16
- Analyst Decision
- KC Strong Buy
- CRNX Strong Buy
- Analyst Count
- KC 4
- CRNX 10
- Target Price
- KC $9.10
- CRNX $75.00
- AVG Volume (30 Days)
- KC 1.9M
- CRNX 676.7K
- Earning Date
- KC 08-19-2025
- CRNX 08-07-2025
- Dividend Yield
- KC N/A
- CRNX N/A
- EPS Growth
- KC N/A
- CRNX N/A
- EPS
- KC N/A
- CRNX N/A
- Revenue
- KC $1,099,631,090.00
- CRNX $760,000.00
- Revenue This Year
- KC $22.58
- CRNX $402.12
- Revenue Next Year
- KC $15.73
- CRNX $770.88
- P/E Ratio
- KC N/A
- CRNX N/A
- Revenue Growth
- KC 14.67
- CRNX N/A
- 52 Week Low
- KC $2.02
- CRNX $24.10
- 52 Week High
- KC $22.26
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- KC 41.42
- CRNX 41.11
- Support Level
- KC $12.23
- CRNX $32.05
- Resistance Level
- KC $13.09
- CRNX $31.56
- Average True Range (ATR)
- KC 0.43
- CRNX 1.08
- MACD
- KC -0.01
- CRNX -0.18
- Stochastic Oscillator
- KC 22.23
- CRNX 5.25
About KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.